Reducing and eliminating neuropathic pain

Puerto Rico Health Sciences Journal

Volumn 28, Issue 4, 2009, Pages 289-300

  Santiago Figueroa, José ^a   Kuffler, Damien P ^a  

^a UNIVERSITY OF PUERTO RICO   (Puerto Rico)

Author keywords

Chronic pain; Nerve injury; Peripheral nerve trauma

Indexed keywords

CHRONIC DISEASE; HUMAN; NEURALGIA; NEUROLOGIC DISEASE; REVIEW;

CHRONIC DISEASE; HUMANS; NERVOUS SYSTEM DISEASES; NEURALGIA;

EID: 72849146271     PISSN: 07380658     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Maag R, Baron R. Neuropathic pain: translational research and impact for patient care. Curr Pain Headache Rep 2006;10: 191-198.
2. Niederberger E, Kuhlein H, Geisslinger G. Update on the pathobiology of neuropathic pain. Expert Rev Proteomics 2008;5: 799-818.
3. Jiménez-Díaz L, Geranton SM, Passmore GM, Leith JL, et al. Local translation in primary afferent fibers regulates nociception. PLoS ONE 2008;3:e1961.
4. Zieglgansberger W, Berthele A, Tolle TR. Understanding neuropathic pain. CNS Spectr 2005;10:298-308.
5. Goodchild CS, Nelson J, Cooke I, Ashby M, et al. Combination therapy with flupirtine and opioid: open-label case series in the treatment of neuropathic pain associated with cancer. Pain Med 2008;9:939-949.
6. de Leon-Casasola OA. Current developments in opioid therapy for management of cancer pain. Clin J Pain 2008;24(Suppl 10): S3-7.
7. Gosselin RD, Dansereau MA, Pohl M, Kitabgi P, et al. Chemokine network in the nervous system: a new target for pain relief. Curr Med Chem 2008;15:2866-2875.
8. Tzellos TG, Papazisis G, Amaniti E, Kouvelas D. Efficacy of pregabalin and gabapentin for neuropathic pain in spinal-cord injury: an evidence-based evaluation of the literature. Eur J Clin Pharmacol 2008;64:851-858.
9. Baastrup C, Finnerup NB. Pharmacological management of neuropathic pain following spinal cord injury. CNS Drugs 2008;22:455-475.
10. Stepanovic-Petrovic RM, Tomic MA, Vuckovic SM, Paranos S, et al. The antinociceptive effects of anticonvulsants in a mouse visceral pain model. Anesth Analg 2008;106:1897-1903.
11. Freye E, Anderson-Hillemacher A, Ritzdorf I, Levy JV. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients. Pain Pract 2007;7: 123-129.
12. Jackson KC, 2nd. Pharmacotherapy for neuropathic pain. Pain Pract 2006;6:27-33.
13. Shim B, Kim DW, Kim BH, Nam TS, et al. Mechanical and heat sensitization of cutaneous nociceptors in rats with experimental peripheral neuropathy. Neuroscience 2005;132:193-201.
14. Katz EJ, Gold MS. Inflammatory hyperalgesia: a role for the Cfiber sensory neuron cell body? J Pain 2006;7:170-178.
15. Twining CM, Sloane EM, Schoeniger DK, Milligan ED, et al. Activation of the spinal cord complement cascade might contribute to mechanical allodynia induced by three animal models of spinal sensitization. J Pain 2005;6:174-183.
16. Lewis C. Physiotherapy and spinal nerve root adhesion: a caution. Physiother Res Int 2004;9:164-173.
17. Navarro X, Vivo M, Valero-Cabre A. Neural plasticity after peripheral nerve injury and regeneration. Prog Neurobiol 2007;82:163-201.
18. Henry JL. Future basic science directions into mechanisms of neuropathic pain. J Orofac Pain 2004;18:306-310.
19. Gybels J, Kupers R, Nuttin B. What can the neurosurgeon offer in peripheral neuropathic pain? Acta Neurochir Suppl (Wien) 1993;58:136-140.
20. Yoon YW, Na HS, Chung JM. Contributions of injured and intact afferents to neuropathic pain in an experimental rat model. Pain 1996;64:27-36.
21. Campbell JN, Meyer RA. Mechanisms of neuropathic pain. Neuron 2006;52:77-92.
22. Berrios I, Castro C, Kuffler DP. Morphine: axon regeneration, neuroprotection, neurotoxicity, tolerance, and neuropathic pain. P R Health Sci J 2008;27:119-128.
23. Sung YJ, Ambron RT. Pathways that elicit long-term changes in gene expression in nociceptive neurons following nerve injury: contributions to neuropathic pain. Neurol Res 2004;26:195-203.
24. Attal N, Filliatreau G, Perrot S, Jazat F, et al. Behavioural pain-related disorders and contribution of the saphenous nerve in crush and chronic constriction injury of the rat sciatic nerve. Pain 1994;59:301-312.
25. Yasuda T, Miki S, Yoshinaga N, Senba E. Effects of amitriptyline and gabapentin on bilateral hyperalgesia observed in an animal model of unilateral axotomy. Pain 2005;115:161-170.
26. Ma W, Eisenach JC. Morphological and pharmacological evidence for the role of peripheral prostaglandins in the pathogenesis of neuropathic pain. Eur J Neurosci 2002;15:1037-1047.
27. Devor M, Govrin-Lippmann R, Angelides K. Na+ channel immunolocalization in peripheral mammalian axons and changes following nerve injury and neuroma formation. J Neurosci 1993;13:1976-1992.
28. Shah BS, Rush AM, Liu S, Tyrrell L, et al. Contactin associates with sodium channel Nav1.3 in native tissues and increases channel density at the cell surface. J Neurosci 2004;24:7387-7399.
29. Jiang YQ, Sun Q, tu HY, Wan Y. Characteristics of HCN channels and their participation in neuropathic pain. Neurochem Res 2008;33:1979-1989.
30. Amir R, Argoff CE, Bennett GJ, Cummins TR, et al. The role of sodium channels in chronic inflammatory and neuropathic pain. J Pain 2006;7:S1-29.
31. Akada Y, Ogawa S, Amano K, Fukudome Y, et al. Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats. Eur J Pharmacol 2006;536:248-255.
32. Kalso E. Sodium channel blockers in neuropathic pain. Curr Pharm Des 2005;11:3005-3011.
33. Finnerup NB, Biering-Sorensen F, Johannesen IL, Terkelsen AJ, et al. Intravenous lidocaine Relieves Spinal Cord injury Pain: A Randomized Controlled Trial. Anesthesiology 2005;102: 1023-1030.
34. Gunes Y, Mert T, Daglioglu YK, Ozbek H, et al. Effect of tramadol on regeneration after experimental sciatic nerve injury. Agri 2005;17:33-38.
35. Thomas J, Kronenberg R, Cox MC, Naco GC, et al. Intravenous lidocaine relieves severe pain: results of an inpatient hospice chart review. J Palliat Med 2004;7:660-667.
36. Wood PL. The NMDA receptor complex: a long and winding road to therapeutics. IDrugs 2005;8:229-235.
37. Stummann TC, Salvati P, Fariello RG, Faravelli L. The antinociceptive agent ralfinamide inhibits tetrodotoxin-resistant and tetrodotoxin-sensitive Na+ currents in dorsal root ganglion neurons. Eur J Pharmacol 2005;510:197-208.
38. Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? Acta Physiol (Oxf) 2006;187:321-327.
39. Li L, Xian CJ, Zhong JH, Zhou XF. Upregulation of brain-derived neurotrophic factor in the sensory pathway by selective motor nerve injury in adult rats. Neurotox Res 2006;9:269-283.
40. Narita M, Yoshida T, Nakajima M, Narita M, et al. Direct evidence for spinal cord microglia in the development of a neuropathic pain-like state in mice. J Neurochem 2006;97:1337-1348.
41. Milligan ED, Twining C, Chacur M, Biedenkapp J, et al. Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 2003;23:1026-1040.
42. Raghavendra V, Tanga F, Deleo JA. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp ther 2003;306:624-630.
43. Watkins LR, Milligan ED, Maier SF. Glial proinflammatory cytokines mediate exaggerated pain states: implications for clinical pain. Adv Exp Med Biol 2003;521:1-21.
44. Xu Jt, Xin WJ, Zang Y, Wu CY, et al. The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat. Pain 2006;123:306-321.
45. Tanga FY, Raghavendra V, Nutile-McMenemy N, Marks A, et al. Role of astrocytic S100beta in behavioral hypersensitivity in rodent models of neuropathic pain. Neuroscience 2006;140: 1003-1010.
46. Gordh T, Chu H, Sharma HS. Spinal nerve lesion alters blood-spinal cord barrier function and activates astrocytes in the rat. Pain 2006;124:211-221.
47. Ledeboer A, Sloane EM, Milligan ED, Frank MG, et al. Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain 2005;115:71-83.
48. Tawfik VL, Nutile-McMenemy N, Lacroix-Fralish ML, Deleo JA. Efficacy of propentofylline, a glial modulating agent, on existing mechanical allodynia following peripheral nerve injury. Brain Behav Immun 2007;21:238-246.
49. Xie W, liu X, Xuan H, luo S, et al. Effect of betamethasone on neuropathic pain and cerebral expression of NF-kappaB and cytokines. Neurosci Lett 2006;393:255-259.
50. Ruohonen S, Khademi M, Jagodic M, Taskinen HS, et al. Cytokine responses during chronic denervation. J Neuroinflammation 2005;2:26.
51. Tanga FY, Nutile-McMenemy N, DeLeo JA. The CNS role of toll-like receptor 4 in innate neuroimmunity and painful neuropathy. Proc Natl Acad Sci U S A 2005;102:5856-5861.
52. Zhuang ZY, Gerner P, Woolf CJ, Ji RR. ERK is sequentially activated in neurons, microglia, and astrocytes by spinal nerve ligation and contributes to mechanical allodynia in this neuropathic pain model. Pain 2005;114:149-159.
53. Eaton MJ, Santiago DI, Dancausse HA, Whittemore SR. Lumbar transplants of immortalized serotonergic neurons alleviate chronic neuropathic pain. Pain 1997;72:59-69.
54. Colpaert FC. 5-HT(1A) receptor activation: new molecular and neuroadaptive mechanisms of pain relief. Curr opin investig Drugs 2006;7:40-47.
55. Coluzzi F, Pappagallo M. Opioid therapy for chronic noncancer pain: practice guidelines for initiation and maintenance of therapy. Minerva Anestesiol 2005;71:425-433.
56. Priano L, Gasco MR, Mauro A. Transdermal treatment options for neurological disorders: impact on the elderly. Drugs Aging 2006;23:357-375.
57. Sittl R. Transdermal buprenorphine in the treatment of chronic pain. Expert Rev Neurother 2005;5:315-323.
58. Galer BS, Lee D, Ma T, Nagle B, et al. MorphiDex (Morphine sulfate/dextromethorphan hydrobromide combination) in the treatment of chronic pain: three multicenter, randomized, double-blind, controlled clinical trials fail to demonstrate enhanced opioid analgesia or reduction in tolerance. Pain 2005;115:284-295.
59. Sotozono C, He J, Tei M, Honma Y, et al. Effect of metalloproteinase inhibitor on corneal cytokine expression after alkali injury. Invest Ophthalmol Vis Sci 1999;40:2430-2434.
60. Chen LE, Liu K, Seaber AV, Katragadda S, et al. Recombinant human glial growth factor 2 (rhGGF2) improves functional recovery of crushed peripheral nerve (a double-blind study). Neurochem Int 1998;33:341-351.
61. Gilron I, Watson CP, Cahill CM, Moulin DE. Neuropathic pain: a practical guide for the clinician. Cmaj 2006;175:265-275.
62. Bennett MI. Gabapentin significantly improves analgesia in people receiving opioids for neuropathic cancer pain. Cancer treat Rev 2005;31:58-62.
63. Sen S, Aydin ON, Aydin K. Beneficial effect of low-dose ketamine addition to epidural administration of morphine-bupiva caine mixture for cancer pain in two cases. Pain Med 2006;7: 166-169.
64. Legge J, Ball N, Elliott DP. The potential role of ketamine in hospice analgesia: a literature review. Consult Pharm 2006;21: 51-57.
65. Moulin DE, Palma D, Watling C, Schulz V. Methadone in the management of intractable neuropathic noncancer pain. Can J Neurol Sci 2005;32:340-343.
66. Sang CN. NMDA-receptor antagonists in neuropathic pain: experimental methods to clinical trials. J Pain Symptom Manage 2000;19:S21-25.
67. Gagnon B, Bruera E. Differences in the ratios of morphine to methadone in patients with neuropathic pain versus non-neuropathic pain. J Pain Symptom Manage 1999;18:120-125.
68. Meunier A, Latremoliere A, Mauborgne A, Bourgoin S, et al. Attenuation of pain-related behavior in a rat model of trigeminal neuropathic pain by viral-driven enkephalin overproduction in trigeminal ganglion neurons. Mol Ther 2005;11:608-616.
69. Przewlocki R, Przewlocka B. Opioids in chronic pain. Eur J Pharmacol 2001;429:79-91.
70. Coluzzi F, Mattia C. Mechanism-based treatment in chronic neuropathic pain: the role of antidepressants. Curr Pharm Des 2005;11:2945-2960.
71. Mico JA, Ardid D, Berrocoso E, and Eschalier A. Antidepressants and pain. Trends Pharmacol Sci 2006;27:348-354.
72. Gilron I and Flatters SJ. Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag 2006;11:16A-29A.
73. Maizels M and McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005;71:483-490.
74. Blackburn-Munro G, Dalby-Brown W, Mirza NR, Mikkelsen JD, et al. Retigabine: chemical synthesis to clinical application. CNS Drug Rev 2005;11:1-20.
75. Pedersen LH, Nielsen AN, and Blackburn-Munro G. Anti-nociception is selectively enhanced by parallel inhibition of multiple subtypes of monoamine transporters in rat models of persistent and neuropathic pain. Psychopharmacology (Berl) 2005;182:551-561.
76. Bomholt SF, Mikkelsen JD, and Blackburn-Munro G. Antinociceptive effects of the antidepressants amitriptyline, duloxetine, mirtazapine and citalopram in animal models of acute, persistent and neuropathic pain. Neuropharmacology 2005;48:252-263.
77. Hadj Tahar A. Pregabalin for peripheral neuropathic pain. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA) 2005: 4.
78. Hurley RW, Cohen SP, Williams KA, Rowlingson AJ, et al. The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis. Reg Anesth Pain Med 2006;31:237-247.
79. Newton RA, Bingham S, Case PC, Sanger GJ, et al. Dorsal root ganglion neurons show increased expression of the calcium channel alpha2delta-1 subunit following partial sciatic nerve injury. Brain Res Mol Brain Res 2001;95:1-8.
80. Kim DS, Yoon CH, lee SJ, Park SY, et al. Changes in voltagegated calcium channel alpha(1) gene expression in rat dorsal root ganglia following peripheral nerve injury. Brain Res Mol Brain Res 2001;96:151-156.
81. Hilaire C, Inquimbert P, Al-Jumaily M, Greuet D, et al. Calcium dependence of axotomized sensory neurons excitability. Neurosci Lett 2005;380:330-334.
82. Richter RW, Portenoy R, Sharma U, Lamoreaux L, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-260.
83. Milligan ED, Sloane EM, Langer SJ, Cruz PE, et al. Controlling neuropathic pain by adeno-associated virus driven production of the anti-inflammatory cytokine, interleukin-10. Mol Pain 2005;1:9.
84. Milligan ED, langer SJ, Sloane EM, He L, et al. Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005;21:2136-2148.
85. Arruda JL, Sweitzer S, Rutkowski MD, DeLeo JA. Intrathecal anti-IL-6 antibody and IgG attenuates peripheral nerve injury-induced mechanical allodynia in the rat: possible immune modulation in neuropathic pain. Brain Res 2000;879:216-225.
86. Yamanaka H, Obata K, Fukuoka T, Dai Y, et al. Induction of plasminogen activator inhibitor-1 and -2 in dorsal root ganglion neurons after peripheral nerve injury. Neuroscience 2005;132: 183-191.
87. Kirwin JL, Goren JL. Duloxetine: a dual serotonin-norepinephrine reuptake inhibitor for treatment of major depressive disorder. Pharmacotherapy 2005;25:396-410.
88. Obata H, Saito S, Koizuka S, Nishikawa K, et al. The monoamine-mediated antiallodynic effects of intrathecally administered milnacipran, a serotonin noradrenaline reuptake inhibitor, in a rat model of neuropathic pain. Anesth Analg 2005;100:1406-1410.
89. Jahnel R, Dreger M, Gillen C, Bender O, et al. Biochemical characterization of the vanilloid receptor 1 expressed in a dorsal root ganglia derived cell line. Eur J Biochem 2001;268:5489-5496.
90. El-Kouhen O, Lehto SG, Pan JB, Chang R, et al. Blockade of mGluR1 receptor results in analgesia and disruption of motor and cognitive performances: effects of A-841720, a novel non-competitive mGluR1 receptor antagonist. Br J Pharmacol 2006;149: 761-774.
91. Valenzano KJ, Sun Q. Current perspectives on the therapeutic utility of VR1 antagonists. Curr Med Chem 2004;11:3185-3202.
92. Tender GC, Walbridge S, Olah Z, Karai L, et al. Selective ablation of nociceptive neurons for elimination of hyperalgesia and neurogenic inflammation. J Neurosurg 2005;102:522-525.
93. Karai L, Brown DC, Mannes AJ, Connelly ST, et al. Deletion of vanilloid receptor 1-expressing primary afferent neurons for pain control. J Clin Invest 2004;113:1344-1352.
94. Ruiz G, Banos JE. The effect of endoneurial nerve growth factor on calcitonin gene-related peptide expression in primary sensory neurons. Brain Res 2005;1042:44-52.
95. McLachlan EM, Hu P. Axonal sprouts containing calcitonin gene-related peptide and substance P form pericellular baskets around large diameter neurons after sciatic nerve transection in the rat. Neuroscience 1998;84:961-965.
96. Ma W, Bisby MA. Increase of calcitonin gene-related peptide immunoreactivity in the axonal fibers of the gracile nuclei of adult and aged rats after complete and partial sciatic nerve injuries. Exp Neurol 1998;152:137-149.
97. Sevcik MA, Ghilardi JR, Peters CM, Lindsay TH, et al. Anti-NgF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 2005;115:128-141.
98. Zhou XF, Deng YS, Xian CJ, Zhong JH. Neurotrophins from dorsal root ganglia trigger allodynia after spinal nerve injury in rats. Eur J Neurosci 2000;12:100-105.
99. Yajima Y, Narita M, Usui A, Kaneko C, et al. Direct evidence for the involvement of brain-derived neurotrophic factor in the development of a neuropathic pain-like state in mice. J Neurochem 2005;93:584-594.
100. Boucher TJ, Okuse K, Bennett DL, Munson JB, et al. Potent analgesic effects of gDNF in neuropathic pain states. Science 2000;290:124-127.
101. Pezet S, Krzyzanowska A, Wong LF, Grist J, et al. Reversal of neurochemical changes and pain-related behavior in a model of neuropathic pain using modified lentiviral vectors expressing GDNF. Mol Ther 2006;13:1101-1109.
102. Hoke A, Cheng C, Zochodne DW. Expression of glial cell line-derived neurotrophic factor family of growth factors in peripheral nerve injury in rats. Neuroreport 2000;11:1651-1654.
103. Dong ZQ, Ma F, Xie H, Wang YQ, et al. Changes of expression of glial cell line-derived neurotrophic factor and its receptor in dorsal root ganglions and spinal dorsal horn during electroacupuncture treatment in neuropathic pain rats. Neurosci lett 2005;376:143-148.
104. Lee HL, Lee KM, Son SJ, Hwang SH, et al. Temporal expression of cytokines and their receptors mRNas in a neuropathic pain model. Neuroreport 2004;15:2807-2811.
105. Ignatowski TA, Sud R, Reynolds JL, Knight PR, et al. The dissipation of neuropathic pain paradoxically involves the presence of tumor necrosis factor-alpha (TNF). Neuropharmacology 2005;48:448-460.
106. Choi BH, Zhu SJ, Kim SH, Kim BY, et al. Nerve repair using a vein graft filled with collagen gel. J Reconstr Microsurg 2005;21:267-272.
107. Zhu SS, Zeng YM, Wang JK, Yan R, et al. Inhibition of thermal hyperalgesia and tactile allodynia by intrathecal administration of gamma-aminobutyric acid transporter-1 inhibitor NO-711 in rats with chronic constriction injury. Sheng Li Xue Bao 2005;57: 233-239.
108. Tamai H, Sawamura S, Takeda K, Orii R, et al. Anti-allodynic and anti-hyperalgesic effects of nociceptin receptor antagonist, JTC-801, in rats after spinal nerve injury and inflammation. Eur J Pharmacol 2005;510:223-228.
109. Corradini L, Briscini L, Ongini E, Bertorelli R. The putative OP(4) antagonist, [Nphe(1)]nociceptin(1-13)NH(2), prevents the effects of nociceptin in neuropathic rats. Brain Res 2001;905:127-133.
110. Wang S, Lim G, Yang L, Sung B, et al. Downregulation of spinal glutamate transporter EAAC1 following nerve injury is regulated by central glucocorticoid receptors in rats. Pain 2006;120:78-85.
111. Binns BC, Huang Y, Goettl VM, Hackshaw KV, et al. Glutamate uptake is attenuated in spinal deep dorsal and ventral horn in the rat spinal nerve ligation model. Brain Res 2005;1041:38-47.
112. Sung B, Lim G, Mao J. Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J Neurosci 2003;23:2899-2910.
113. Sotgiu ML, Bellomi P, and Biella GE. The mGluR5 selective antagonist 6-methyl-2-(phenylethynyl)-pyridine reduces the spinal neuron pain-related activity in mononeuropathic rats. Neurosci Lett 2003;342:85-88.
114. Simmons RM, Webster AA, Kalra AB, Iyengar S. Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 2002;73:419-427.
115. Niederberger E, Schmidtko A, Rothstein JD, Geisslinger G, et al. Modulation of spinal nociceptive processing through the glutamate transporter GLT-1. Neuroscience 2003;116:81-87.
116. Neugebauer V, Carlton SM. Peripheral metabotropic glutamate receptors as drug targets for pain relief. Expert Opin Ther Targets 2002;6:349-361.
117. Rueter LE, Kohlhaas KL, Curzon P, Surowy CS, et al. Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain 2003;103:269-276.
118. Mense S. Neurobiological basis for the use of botulinum toxin in pain therapy. J Neurol 2004;251(Suppl 1):I1-7.
119. Dube GR, Kohlhaas KL, Rueter LE, Surowy CS, et al. Loss of functional neuronal nicotinic receptors in dorsal root ganglion neurons in a rat model of neuropathic pain. Neurosci lett 2005;376:29-34.
120. Kim SK, Min BI, Kim JH, Hwang BG, et al. Effects of alpha1- and alpha2-adrenoreceptor antagonists on cold allodynia in a rat tail model of neuropathic pain. Brain Res 2005;1039: 207-210.
121. Yamanaka K, Inaba T, Nomura E, Hurwitz D, et al. Basic fibro-blast growth factor treatment for skin ulcerations in scleroderma. Cutis 2005;76:373-376.
122. Yamanaka H, Obata K, Fukuoka T, Dai Y, et al. Tissue plasminogen activator in primary afferents induces dorsal horn excitability and pain response after peripheral nerve injury. Eur J Neurosci 2004;19:93-102.
123. Zhang J, Hoffert C, Vu HK, Groblewski T, et al. Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci 2003;17: 2750-2754.
124. Sanderson JE, Ibrahim B, Waterhouse D, Palmer RB. Spinal electrical stimulation for intractable angina--long-term clinical outcome and safety. Eur Heart J 1994;15:810-814.
125. Valenzano KJ, Tafesse L, Lee G, Harrison JE, et al. Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology 2005;48:658-672.
126. Liang YC, Huang CC, Hsu KS. Therapeutic potential of cannabinoids in trigeminal neuralgia. Curr Drug targets CNS Neurol Disord 2004;3:507-514.
127. Kingery WS, Fields RD, Kocsis JD. Diminished dorsal root GABA sensitivity following chronic peripheral nerve injury. Exp Neurol 1988;100:478-490.
128. Millheiser LS, Chen B. Severe vaginal pain caused by a neuroma in the rectovaginal septum after posterior colporrhaphy. Obstet Gynecol 2006;108:809-811.
129. Marcol W, Kotulska K, Larysz-Brysz M, Bierzynska-Macyszyn G, et al. Prevention of painful neuromas by oblique transection of peripheral nerves. J Neurosurg 2006;104:285-289.
130. Dellon AL, Kim J, Ducic I. Painful neuroma of the posterior cutaneous nerve of the forearm after surgery for lateral humeral epicondylitis. J Hand Surg Am 2004;29:387-390.
131. Won R, Lee BH, Park S, Kim SH, et al. Role of different peripheral components in the expression of neuropathic pain syndrome. Yonsei Med J 2000;41:354-361.
132. Sindou M, Jeanmonod D. Microsurgical DREZ-otomy for the treatment of spasticity and pain in the lower limbs. Neurosurgery 1989;24:655-670.
133. Sindou M, Rosati C, Millet MF, Beneton C. Selective posterior rhizotomy at the posterior radiculomedullary junction in the treatment of hyperspasticity and pain in the lower limbs. Neurochirurgie 1987;33:433-454.
134. Whitworth LA, Feler CA. Application of spinal ablative techniques for the treatment of benign chronic painful conditions: history, methods, and outcomes. Spine 2002;27:2607-2613.
135. Spaic M, Markovic N, Tadic R. Microsurgical DREZotomy for pain of spinal cord and Cauda equina injury origin: clinical characteristics of pain and implications for surgery in a series of 26 patients. Acta Neurochir (Wien) 2002;144:453-462.
136. Meyerson BA. Neurosurgical approaches to pain treatment. Acta Anaesthesiol Scand 2001;45:1108-1113.
137. Danshaw CB. An anesthetic approach to amputation and pain syndromes. Phys Med Rehabil Clin N Am 2000;11:553-557.
138. Hargraves WA, Hentall ID. Analgesic effects of dietary caloric restriction in adult mice. Pain 2005;114:455-461.
139. Goroszeniuk T, Kothari S, Hamann W. Subcutaneous neuromodulating implant targeted at the site of pain. Reg Anesth Pain Med 2006;31:168-171.
140. Ainsworth L, Budelier K, Clinesmith M, Fiedler A, et al. Transcutaneous electrical nerve stimulation (TENS) reduces chronic hyperalgesia induced by muscle inflammation. Pain 2006;120:182-187.
141. Sluka KA, Vance CG, Lisi TL. High-frequency, but not low-frequency, transcutaneous electrical nerve stimulation reduces aspartate and glutamate release in the spinal cord dorsal horn. J Neurochem 2005;95:1794-1801.
142. Reichstein L, Labrenz S, Ziegler D, Martin S. Effective treatment of symptomatic diabetic polyneuropathy by high-frequency external muscle stimulation. Diabetologia 2005;48:824-828.
143. Miranda-Cardenas Y, Rojas-Piloni G, Martínez-Lorenzana G, Rodríguez-Jiménez J, et al. oxytocin and electrical stimulation of the paraventricular hypothalamic nucleus produce antinociceptive effects that are reversed by an oxytocin antagonist. Pain 2006;122:182-189.
144. Villarreal CF, Kina VA, Prado WA. Antinociception induced by stimulating the anterior pretectal nucleus in two models of pain in rats. Clin Exp Pharmacol Physiol 2004;31:608-613.
145. Rushton DN. Electrical stimulation in the treatment of pain. Disabil Rehabil 2002;24:407-415.
146. Stanik-Hutt JA. Management options for angina refractory to maximal medical and surgical interventions. AACN Clin issues 2005;16:320-332.
147. Bueno EA, Mamtani R, Frishman WH. Alternative approaches to the medical management of angina pectoris: acupuncture, electrical nerve stimulation, and spinal cord stimulation. Heart Dis 2001;3:236-241.
148. Mailis-Gagnon A, Furlan AD, Sandoval JA, Taylor R. Spinal cord stimulation for chronic pain. Cochrane Database Syst Rev 2004; CD003783
149. Vijayan R, Ahmad TS. Spinal cord stimulation for treatment of failed back surgery syndrome--two case reports. Med J Malaysia 1999;54:509-513.
150. Bosi E, Conti M, Vermigli C, Cazzetta G, et al. Effectiveness of frequency-modulated electromagnetic neural stimulation in the treatment of painful diabetic neuropathy. Diabetologia 2005;48:817-823.
151. Daousi C, Benbow SJ, MacFarlane IA. Electrical spinal cord stimulation in the long-term treatment of chronic painful diabetic neuropathy. Diabet Med 2005;22:393-398.
152. Sundaraj SR, Johnstone C, Noore F, Wynn P, et al. Spinal cord stimulation: a seven-year audit. J Clin Neurosci 2005;12:264-270.
153. Kemler MA, Barendse GA, van Kleef M, de Vet HC, et al. Spinal cord stimulation in patients with chronic reflex sympathetic dystrophy. N Engl J Med 2000;343:618-624.
154. Senapati AK, Huntington PJ, Peng YB. Spinal dorsal horn neuron response to mechanical stimuli is decreased by electrical stimulation of the primary motor cortex. Brain Res 2005;1036:173-179.
155. Henderson LP, Kuffler DP, Nicholls J, Zhang R. Structural and functional analysis of synaptic transmission between identified leech neurones in culture. J Physiol 1983;340:347-358.
156. McDougall S, Dallon J, Sherratt J, Maini P. Fibroblast migration and collagen deposition during dermal wound healing: mathematical modelling and clinical implications. Philos transact a Math Phys Eng Sci 2006;364:1385-1405.
157. Spilker MH, Yannas IV, Kostyk SK, Norregaard TV, et al. The effects of tubulation on healing and scar formation after transection of the adult rat spinal cord. Restor Neurol Neurosci 2001;18:23-38.